196 related articles for article (PubMed ID: 22940081)
1. CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators.
Watahiki H; Yagishita S; Futai E; Ishiura S
Neurosci Lett; 2012 Sep; 526(2):96-9. PubMed ID: 22940081
[TBL] [Abstract][Full Text] [Related]
2. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization.
Richter L; Munter LM; Ness J; Hildebrand PW; Dasari M; Unterreitmeier S; Bulic B; Beyermann M; Gust R; Reif B; Weggen S; Langosch D; Multhaup G
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14597-602. PubMed ID: 20679249
[TBL] [Abstract][Full Text] [Related]
3. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
Czirr E; Cottrell BA; Leuchtenberger S; Kukar T; Ladd TB; Esselmann H; Paul S; Schubenel R; Torpey JW; Pietrzik CU; Golde TE; Wiltfang J; Baumann K; Koo EH; Weggen S
J Biol Chem; 2008 Jun; 283(25):17049-54. PubMed ID: 18426795
[TBL] [Abstract][Full Text] [Related]
4. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
Borgegard T; Juréus A; Olsson F; Rosqvist S; Sabirsh A; Rotticci D; Paulsen K; Klintenberg R; Yan H; Waldman M; Stromberg K; Nord J; Johansson J; Regner A; Parpal S; Malinowsky D; Radesater AC; Li T; Singh R; Eriksson H; Lundkvist J
J Biol Chem; 2012 Apr; 287(15):11810-9. PubMed ID: 22334705
[TBL] [Abstract][Full Text] [Related]
5. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Weggen S; Eriksen JL; Das P; Sagi SA; Wang R; Pietrzik CU; Findlay KA; Smith TE; Murphy MP; Bulter T; Kang DE; Marquez-Sterling N; Golde TE; Koo EH
Nature; 2001 Nov; 414(6860):212-6. PubMed ID: 11700559
[TBL] [Abstract][Full Text] [Related]
6. Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42.
Funamoto S; Morishima-Kawashima M; Tanimura Y; Hirotani N; Saido TC; Ihara Y
Biochemistry; 2004 Oct; 43(42):13532-40. PubMed ID: 15491160
[TBL] [Abstract][Full Text] [Related]
7. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
8. Substrate-targeting gamma-secretase modulators.
Kukar TL; Ladd TB; Bann MA; Fraering PC; Narlawar R; Maharvi GM; Healy B; Chapman R; Welzel AT; Price RW; Moore B; Rangachari V; Cusack B; Eriksen J; Jansen-West K; Verbeeck C; Yager D; Eckman C; Ye W; Sagi S; Cottrell BA; Torpey J; Rosenberry TL; Fauq A; Wolfe MS; Schmidt B; Walsh DM; Koo EH; Golde TE
Nature; 2008 Jun; 453(7197):925-9. PubMed ID: 18548070
[TBL] [Abstract][Full Text] [Related]
9. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
Wanngren J; Ottervald J; Parpal S; Portelius E; Strömberg K; Borgegård T; Klintenberg R; Juréus A; Blomqvist J; Blennow K; Zetterberg H; Lundkvist J; Rosqvist S; Karlström H
J Biol Chem; 2012 Sep; 287(39):32640-50. PubMed ID: 22851182
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.
Ling IF; Golde TE; Galasko DR; Koo EH
Alzheimers Res Ther; 2015; 7(1):55. PubMed ID: 26244059
[TBL] [Abstract][Full Text] [Related]
11. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.
Mitani Y; Yarimizu J; Akashiba H; Shitaka Y; Ni K; Matsuoka N
J Neurochem; 2013 May; 125(3):465-72. PubMed ID: 23240999
[TBL] [Abstract][Full Text] [Related]
13. γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP).
Lessard CB; Cottrell BA; Maruyama H; Suresh S; Golde TE; Koo EH
PLoS One; 2015; 10(12):e0144758. PubMed ID: 26678856
[TBL] [Abstract][Full Text] [Related]
14. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.
Suárez-Calvet M; Belbin O; Pera M; Badiola N; Magrané J; Guardia-Laguarta C; Muñoz L; Colom-Cadena M; Clarimón J; Lleó A
J Neurochem; 2014 Jan; 128(2):330-9. PubMed ID: 24117942
[TBL] [Abstract][Full Text] [Related]
15. Synthetic ceramide analogues increase amyloid-β 42 production by modulating γ-secretase activity.
Takasugi N; Sasaki T; Shinohara M; Iwatsubo T; Tomita T
Biochem Biophys Res Commun; 2015 Feb; 457(2):194-9. PubMed ID: 25545059
[TBL] [Abstract][Full Text] [Related]
16. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
17. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
Weggen S; Eriksen JL; Sagi SA; Pietrzik CU; Golde TE; Koo EH
J Biol Chem; 2003 Aug; 278(33):30748-54. PubMed ID: 12777371
[TBL] [Abstract][Full Text] [Related]
18. Potent γ-secretase inhibitors/modulators interact with amyloid-β fibrils but do not inhibit fibrillation: a high-resolution NMR study.
Yesuvadian R; Krishnamoorthy J; Ramamoorthy A; Bhunia A
Biochem Biophys Res Commun; 2014 May; 447(4):590-5. PubMed ID: 24747079
[TBL] [Abstract][Full Text] [Related]
19. The A673T mutation in the amyloid precursor protein reduces the production of β-amyloid protein from its β-carboxyl terminal fragment in cells.
Kokawa A; Ishihara S; Fujiwara H; Nobuhara M; Iwata M; Ihara Y; Funamoto S
Acta Neuropathol Commun; 2015 Nov; 3():66. PubMed ID: 26531305
[TBL] [Abstract][Full Text] [Related]
20. NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide.
Barrett PJ; Sanders CR; Kaufman SA; Michelsen K; Jordan JB
Biochemistry; 2011 Nov; 50(47):10328-42. PubMed ID: 21995415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
